Tuberous sclerosis complex, Serbian referral center experience
Abstract
Abstract
BackgroundAim. Common features of tuberous sclerosis complex (TSC) arise from the formation of hamartomas both in the brain and multiple organ systems, mainly due to a mutation in one of two genes, TSC1 or TSC2, with well described inter- and intrafamilial different phenotypic outcomes. The aim of this work was to make a synthesis of the patients data with diagnosed tuberous sclerosis in order to better understand the disease in our environment. Methods. We reviewed retrospectively the clinical records of all patients with TSC, diagnosed and regularly followed at the Clinic of Neurology and Psychiatry for Children and Youth in Belgrade, Serbia during the period of more than two decades. Statistical analyses were performed using descriptive statistics as well as the Fisher’s exact test. Results. Cohort of 44 patients with the diagnosis of definitive TSC were included. The mean age at last follow-up was 19.4 years [age range 1–58, standard deviation (SD) 11.8]. Family history for TSC was noted in 25% of patients. Dermatological manifestations were described in 93.2%, retinal astrocytoma and cardiac rhabdomyomas was found in 36.4% each, nephrological manifestations in 34.1% and lymphangioleiomyomatosis was diagnosed in two female patients. All patients presented with the structural lesions of central nervous system; epilepsy was diagnosed in 88.6%, out of whom 59 % of patients had seizure onset in the first year of life. The West syndrome was diagnosed in 27.3% of patients. Complete seizure control was achieved in 30.8%, in a majority with valproic acid or cabamazepine, but also with topiramate, lamotrigine and vigabatrin. At least two antiepileptic drugs were administered in 82% of patients. Mental retardation was noted in 50% of patients. Psychiatric manifestations were found in 40.9%, with attention deficit hyperactivity disorder diagnosed in 27.3%, autism spectrum disorder in 13.6 %, and psychosis and depression observed in 11.4% each. Conclusion. This kind of synthesis of the data certainly contributes to better understanding of the disease in our environment, as TSC, although well-known disease, still remains diagnostic and therapeutic challenge in daily clinical practice.
References
REFERENCES
Northrup H, Krueger DA. Tuberous Sclerosis Complex Diagnos¬tic Criteria Update: Recommendations of the 2012 Interna¬tional Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49(4): 243–54.
Jentarra GM, Rice SG, Olfers S, Saffen D, Narayanan V. Ev-idence for population variation in TSC1 and TSC2 gene expression. BMC Med Genet 2011; 12: 29.
Wong M. Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation. Epilepsia 2008; 49(1): 8–21.
Muzykewicz DA, Costello DJ, Halpern EF, Thiele EA. Infantile spasms in tuberous sclerosis complex: Prognostic utility of EEG. Epilepsia 2009; 50(2): 290–6.
Bombardieri R, Pinci M, Moavero R, Cerminara C, Curatolo P. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol 2010; 14(2): 146–9.
Cusmai R, Moavero R, Bombardieri R, Vigevano F, Curatolo P. Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. Epilepsy Behav 2011; 22(4): 735–9.
Krueger DA. Management of CNS-related Disease Manifesta-tions in Patients With Tuberous Sclerosis Complex. Curr Treat Options Neurol 2013; 15(5): 618–33.
French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): A phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016; 388(10056): 2153–63.
Vries PJ, Whittemore VH, Leclezio L, Byars AW, Dunn D, Ess KC, et al. Tuberous sclerosis associated neuropsychiatric dis-orders (TAND) and the TAND Checklist. Pediatr Neurol 2015; 52(1): 25–35.
Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis com¬plex. N Engl J Med 2006; 355(13): 1345–56.
Roth J, Roach SE, Bartels U, Jóźwiak S, Koenig MK, Weiner HL, et al. Subependymal giant cell astrocytoma: Diagnosis, screening, and treatment. Recommendations from the International Tu¬berous Sclerosis Complex Consensus Conference 2012. Pedi¬atr Neurol 2013; 49(6): 439–44.
Thiele E, Korf B. Phakomatosis and allied conditions. In: Swai-man K, Ashwal S, Ferriero D, Schor N, editors. Swaiman's pediat¬ric neurology: Principles and Practice. 5th ed. New York, NY: Elsevier Inc; 2012. p. 497–517.
Jóźwiak S, Kotulska K, Kasprzyk-Obara J, Domańska-Pakieła D, To¬myn-Drabik M, Roberts P, et al. Clinical and genotype studies of cardiac tumors in 154 patients with tuberous sclerosis com-plex. Pediatrics 2006; 118(4): 1146–51.
Wataya-Kaneda M, Tanaka M, Hamasaki T, Katayama I. Trends in the prevalence of tuberous sclerosis complex manifesta-tions: An epidemiological study of 166 Japanese patients. PLoS ONE 2013; 8(5): e63910.
Johnson SR, Whale CI, Hubbard RB, Lewis SA, Tattersfield AE. Sur¬vival and disease progression in UK patients with lym-phangioleiomyomatosis. Thorax 2004; 59(9): 800–3.
Joinson C, O'Callaghan FJ, Osborne JP, Martyn C, Harris T, Bolton PF. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med 2003; 33(2): 335–44.
Winterkorn EB, Pulsifer MB, Thiele EA. Cognitive prognosis of patients with tuberous sclerosis complex. Neurology 2007; 68(1): 62–4.
Staley BA, Vail EA, Thiele EA. Tuberous sclerosis complex: Di¬agnostic challenges, presenting symptoms, and commonly missed signs. Pediatrics 2011; 127(1): 117–25.
Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010; 51(7): 1236–41.
D'Agati ED, Moavero R, Cerminara C, Curatolo P. Attention-defi¬cit hyperactivity disorder (ADHD) and tuberous sclerosis complex. J Child Neurol 2009; 24(10): 1282–7.
Curatolo P, Porfirio MC, Manzi B, Seri S. Autism in tuberous scle¬rosis. Eur J Paediatr Neurol 2004; 8(6): 327–32.
Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372(9639): 657–68.
Kothare SV, Singh K, Hochman T, Chalifoux JR, Staley BA, Weiner HL, et al. Genotype/phenotype in tuberous sclerosis complex: Associations with clinical and radiologic manifestations. Epi¬lepsia 2014; 55(7): 1020–4.